Taipei-listed shares in Taiwan Semiconductor Manufacturing Company (2330.TW) surged nearly 10% on Thursday, after the chipmaker posted a 42% increase in revenue in the first quarter. In its monthly ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Ltd., a leader in premium interior design solutions, is thrilled to announce the launch of its new Experience Center in Whitefield, Bangalore. This new showroom reflects the company's ongoing ...

Novo Nordisk is considering launching its weight loss injection Wegovy in India sooner than planned to better challenge U.S. rival Eli Lilly, Reuters reports, citing unnamed sources. --The Danish ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 billion) in Brazil to increase production at its facility in Minas Gerais.

SAO PAULO, April 7 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost ...

Claim your 7-day free trial now. Novo Nordisk A/S NVO on Saturday presented the full results from the Phase 3b STRIDE peripheral artery disease (PAD) outcomes trial. The study evaluated the once ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...